2. Search Result
Search Result
Results for "

nonsteroidal androgen receptor

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

6

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111372
    Finerenone
    5+ Cited Publications

    BAY 94-8862

    		 Mineralocorticoid Receptor Cardiovascular Disease Metabolic Disease
    Finerenone (BAY 94-8862) is a third-generation, selective, and orally active nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (> 500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone
  • HY-14249
    Bicalutamide
    Maximum Cited Publications
    20 Publications Verification

    		 Androgen Receptor Autophagy Cancer
    Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .
    Bicalutamide
  • HY-13702
    Nilutamide

    Nilandron; RU 23908

    		 Androgen Receptor Parasite Infection Endocrinology Cancer
    Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties .
    Nilutamide
  • HY-14383
    Vosilasarm
    5+ Cited Publications

    RAD140; EP0062

    		 Androgen Receptor Neurological Disease Endocrinology Cancer
    Vosilasarm (RAD140) is a potent, orally active, nonsteroidal selective androgen receptor modulator (SARM) with a Ki of 7 nM. Vosilasarm shows good selectivity over other steroid hormone nuclear receptors .
    Vosilasarm
  • HY-100186
    GSK-2881078
    5 Publications Verification

    		 Androgen Receptor Cardiovascular Disease Others Metabolic Disease Inflammation/Immunology Endocrinology Cancer
    GSK-2881078 is an orally active and nonsteroidal selective androgen receptor modulator (SARM) which act as partial AR agonists in androgenic tissues while mainly as complete AR agonists in synthetic metabolic tissues,induces AR-mediated transcriptional activation in PC3(AR)2 cells (EC50 = 3.99 nM) and the effect can be inhibited by the non-steroidal AR antagonist Bicalutamide. GSK-2881078 can be used in research of muscle weakness and cachexia associated with both chronic and acute illness .
    GSK-2881078
  • HY-111372R
    Finerenone (Standard)

    BAY 94-8862 (Standard)

    		 Reference Standards Mineralocorticoid Receptor Cardiovascular Disease
    Finerenone (Standard) is the analytical standard of Finerenone. This product is intended for research and analytical applications. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone (Standard)
  • HY-122025
    AC-262536
    1 Publications Verification

    		 Androgen Receptor Metabolic Disease
    AC-262536 is a selective and non-steroidal androgen receptor modulators (SARMs) with beneficial anabolic effects. AC-262536 exhibits potent agonist activity at the androgen receptor, with an affinity in the low nanomolar range (1-10 nM) .
    AC-262536
  • HY-12023
    GTx-007
    4 Publications Verification

    S-4

    		 Androgen Receptor Cancer
    GTx-007 (S-4) is an orally active and selective nonsteroidal androgen receptor (AR) modulator (SARM) and a partial agonist, with Ki of 4 nM. GTx-007 (S-4) is identified as SARMs with potent and tissue-selective in vivo pharmacological activity .
    GTx-007
  • HY-19337
    Ketodarolutamide
    1 Publications Verification

    BAY 1896953; ORM-15341

    		 Androgen Receptor Cancer
    Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .
    Ketodarolutamide
  • HY-18102
    GLPG0492
    5+ Cited Publications

    		 Androgen Receptor Neurological Disease
    GLPG0492 is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .
    GLPG0492
  • HY-13607
    BMS-641988

    		Androgen Receptor Cancer
    BMS-641988 (compound 23) is an oral active nonsteroidal androgen receptor antagonist with the Ki of 1.7 nM. BMS-641988 shows anticancer activity .
    BMS-641988
  • HY-45509
    TLB 150 Benzoate

    RAD150

    		 Androgen Receptor Neurological Disease
    TLB 150 Benzoate (RAD150) is a nonsteroidal androgen receptor modulator with an IC50 value of 0.13 μM. TLB 150 Benzoate spontaneously cyclizes under physiological conditions to form RAD 179, resulting in a persistent, reversible, and slow neuronal conduction blockade. TLB 150 Benzoate can be used for research on neurological diseases .
    TLB 150 Benzoate
  • HY-171048
    GTx-027

    		Androgen Receptor Endocrinology Cancer
    GTx-027 is an orally active and non-steroidal selective androgen receptor modulator (SARM). GTx-027 shows androgen receptor (AR) transactivation effects with the EC50 of 1.8 nM. GTx-027 acts selectively increase muscle weight (anabolic) without affecting secondary sexual organs (androgenic). GTx-027 has the protential for the study of breast cancer and stress urinary incontinence (SUI) .
    GTx-027
  • HY-18102A
    GLPG0492 (R enantiomer)

    		Drug Isomer Androgen Receptor Neurological Disease
    GLPG0492 R enantiomer is the R enantiomer of GLPG0492. GLPG0492 is an orally active, non-steroidal selective androgen receptor modulator.
    GLPG0492 (R enantiomer)
  • HY-111372A
    (Rac)-Finerenone

    (Rac)-BAY 94-8862

    		 Mineralocorticoid Receptor Cardiovascular Disease
    (Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold) .
    (Rac)-Finerenone
  • HY-14250
    PF-998425

    		Androgen Receptor Endocrinology
    PF-998425 is a potent, selective nonsteroidal androgen receptor (AR) antagonist with an IC50 of 37 nM and 43 nM in AR binding and cellular assays, respectively. PF-998425 has low activity on common receptors and enzymes, such as progesterone receptor. PF-998425 can be used for sebum control and androgenetic alopecia research .
    PF-998425
  • HY-111372S
    Finerenone-d3

    BAY 94-8862-d3

    		 Mineralocorticoid Receptor Others
    Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone-d3
  • HY-111372S1
    Finerenone-d5
    1 Publications Verification

    BAY 94-8862-d5

    		 Isotope-Labeled Compounds Mineralocorticoid Receptor Cardiovascular Disease
    Finerenone-d5 (BAY 94-8862-d5) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .
    Finerenone-d5
  • HY-117953
    RU 59063

    		Prostaglandin Receptor Endocrinology
    RU 59063 is an N-substituted arylthiohydantoin compound with antiandrogenic activity and high relative binding affinity for the rat androgen receptor. RU 59063 is a nonsteroidal androgen receptor that functions as a radioactive AR radioprobe (Ki: 0.71 nM, rAR) when its trifluoromethyl group is replaced by a similar hydrophobic iodine atom .
    RU 59063
  • HY-111421
    ODM-204

    		Androgen Receptor Cytochrome P450 Cancer
    ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme, with IC50s of 80 nM and 22 nM, respectively.
    ODM-204
  • HY-14249S
    Bicalutamide-d4

    		Isotope-Labeled Compounds Androgen Receptor Autophagy Cancer
    Bicalutamide-d4 is the deuterium labeled Bicalutamide. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .
    Bicalutamide-d4
  • HY-111145
    RD162

    		Androgen Receptor Cancer
    RD162, a diarylthiohydantoin, is an orally active non-steroidal antiandrogen (NSAA). RD162 specifically binds to androgen receptor (AR). RD162 induces tumor regression in mouse models of castration-resistant human prostate cancer .
    RD162
  • HY-125627
    CP-394531

    		Glucocorticoid Receptor Androgen Receptor Neurological Disease Metabolic Disease
    CP-394531 is an efficient and highly selective non-steroidal glucocorticoid receptor (GR) antagonist, with a Ki value of 0.1 nM. CP-394531 has a weak binding to androgen receptor (AR) (Ki = 130 nM), and has almost no effect on progesterone receptor (PR) and estrogen receptors (ERα, ERβ). CP-394531 completely blocks the half-maximal agonistic effect induced by Dexamethasone (HY-14648G), with a Kif of 4.1 nM. CP-394531 can be used to study various diseases such as diabetes, obesity, depression, neurodegenerative diseases, glaucoma and Cushing's disease .
    CP-394531
  • HY-123310
    JNJ-26146900

    		Androgen Receptor Cancer
    JNJ-26146900 is a potent and orally active androgen receptor antagonist with a Ki value of 400nM for rat AR. JNJ-26146900 is a nonsteroidal androgen receptor (AR) ligand. JNJ-26146900 reduces prostate tumor size and prevents bone loss. JNJ-26146900 can be used in research of cancer .
    JNJ-26146900
  • HY-13702R
    Nilutamide (Standard)

    Nilandron (Standard); RU 23908 (Standard)

    		 Reference Standards Androgen Receptor Parasite Infection Endocrinology Cancer
    Nilutamide (Standard) is the analytical standard of Nilutamide. This product is intended for research and analytical applications. Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties .
    Nilutamide (Standard)
  • HY-106104
    Inocoterone acetate

    RU-38882; RU-882

    		 Androgen Receptor Inflammation/Immunology Endocrinology
    Inocoterone acetate (RU-38882) is a nonsteroidal antiandrogen. Inocoterone acetate binds to the androgen receptor and has antiandrogenic activity in animal models. Inocoterone acetate reduces inflammatory papules and pustules .
    Inocoterone acetate
  • HY-14249R
    Bicalutamide (Standard)

    		Reference Standards Androgen Receptor Autophagy Cancer
    Bicalutamide (Standard) is the analytical standard of Bicalutamide. This product is intended for research and analytical applications. Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer .
    Bicalutamide (Standard)
  • HY-13607A
    (rel)-BMS-641988

    		Androgen Receptor Cancer
    (rel)-BMS-641988 is a relative configuration of BMS-641988. BMS-641988 is a potent nonsteroidal androgen receptor antagonist. BMS-641988 has the potential for the research of prostate cancer .
    (rel)-BMS-641988
  • HY-14250A
    (Rac)-PF-998425

    		Androgen Receptor Endocrinology
    (Rac)-PF-998425 is a potent, selective, nonsteroidal androgen receptor (AR) antagonist. (Rac)-PF-998425 has IC50 values of 26 and 90 nM in the AR binding and cellular assays, respectively. (Rac)-PF-998425 has the potential for the research of the androgenetic alopecia .
    (Rac)-PF-998425
  • HY-18102BS
    GLPG0492-13C,d3 racemate

    		Isotope-Labeled Compounds Adrenergic Receptor Neurological Disease
    GLPG0492- 13C,d3 racemate is 13C-labeled GLPG0492 (racemate) (HY-18102B). GLPG0492 racemate is an orally active, non-steroidal selective androgen receptor modulator. GLPG0492 racemate exerts functional transactivation by binding to the ligand-binding domain of the receptor, exhibiting preferential partial agonist activity in muscle and bone tissues with low activity in reproductive tissues. GLPG0492 racemate effectively counteracts muscle atrophy-related pathways, significantly enhances muscle strength, maintains motor ability, reduces fibrosis and improves electrophysiological parameters. GLPG0492 racemate prevents immobilization-induced muscle atrophy and regulates muscle mass homeostasis, serving as a valuable tool compound for studies on Duchenne muscular dystrophy, muscle loss and various types of disuse musculoskeletal atrophy .
    GLPG0492-13C,d3 racemate
  • HY-120703
    RU 58642

    		Androgen Receptor Endocrinology
    RU 58642 is an orally active non-steroidal antiandrogen, which displays a strong and selective affinity for androgen receptor .
    RU 58642
  • HY-116219
    WB2838

    		Androgen Receptor Endocrinology Cancer
    WB2838 is a non-steroidal androgen-receptor antagonist (IC50: 0.8 μM for partially purified rat prostate cytosol receptor). WB2838 exhibits anti-cancer activity against androgen-responsive breast cancer. WB2838 also shows the inhibitory activity against the growth of the ventral prostate induced by Testosterone propionate .
    WB2838
  • HY-19337S1
    Ketodarolutamide-d6

    BAY 1896953-d6; ORM-15341-d6

    		 Isotope-Labeled Compounds Androgen Receptor Cancer
    Ketodarolutamide-d6 (BAY 1896953-d6) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .
    Ketodarolutamide-d6
  • HY-19337S
    Ketodarolutamide-d3

    BAY 1896953-d3; ORM-15341-d3

    		 Isotope-Labeled Compounds Androgen Receptor Cancer
    Ketodarolutamide-d3 (BAY 1896953-d3) is the deuterium labeled Ketodarolutamide (HY-19337). Ketodarolutamide (ORM-15341) is a potent, high-affinity nonsteroidal competitive full antagonist of androgen receptor (AR). Ketodarolutamide displays a Ki value of 8 nM for rat wild-type AR and an IC50 value of 38 nM in AR-HEK293 cells . Ketodarolutamide inhibits testosterone-induced nuclear translocation of the AR and antagonizes both overexpressed and mutant ARs . Ketodarolutamide specifically suppresses the proliferation of AR-dependent prostate cancer cells and exhibits antitumor activity in models of castration-resistant prostate cancer (CRPC) . Ketodarolutamide is suitable for the mechanistic and therapeutic research of prostate cancer .
    Ketodarolutamide-d3
  • HY-111372B
    (R)-Finerenone

    (R)-BAY 94-8862

    		 Drug Isomer Mineralocorticoid Receptor Cardiovascular Disease
    (R)-Finerenone ((R)-BAY 94-8862) is the R-isomer of Finerenone (HY-111372). Finerenone is a third-generation selective, orally active, non-steroidal mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM). Compared with glucocorticoid receptors (GR), androgen receptors (AR), and progesterone receptors (AR), Finerenone shows good selectivity (> 500-fold). Finerenone has potential application prospects in studies of heart and kidney diseases, such as type 2 diabetes and chronic kidney disease .
    (R)-Finerenone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: